1951-LB: Impact of Discontinuation of Automated Insulin Delivery Systems in the Emerging Adult with Type 1 Diabetes

Introduction 0.001). Discontinuation was associated with higher HbA1c (p0.001). AID was discontinued at least temporarily by 15.3% of patients (N=94), with highest rates in 19-22 year olds (38 of 174, 21.8%). AID discontinuation reasons included supply (25.5%) or cost/insurance issues (15.3%). Conclusion: Consistent AID usage in emerging adults is associated with sustained improvements in HbA1c levels. Further study on strategies to reduce discontinuation is required. Disclosure L.A. Waterman: None. E.C. Cobry: Advisory Panel; Dexcom, Inc. Other Relationship; Dexcom, Inc. C. Sakamoto: None. L. Pyle: None. G.P. Forlenza: Research Support; Abbott, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Medtronic. Advisory Panel; Medtronic. Research Support; Tandem Diabetes Care, Inc. Consultant; Tandem Diabetes Care, Inc. V.N. Shah: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Sanofi, Medscape. Consultant; embecta, Tandem Diabetes Care, Inc. G.T. Alonso: Advisory Panel; MannKind Corporation. Funding National Institutes of Health (5T32DK063687)